Hologic logo, dark blue
Hologic logo, dark blue
  1. About
  2. Hologic Honored Twice as Company of the Year in Medical Devices and Diagnostics

Hologic Honored Twice as Company of the Year in Medical Devices and Diagnostics

Employees Interacting

Hologic’s global leadership in women’s health continued excellence in COVID-19 testing, and expanding impact on other areas of healthcare have earned it “Company of the Year” honors from both editors and readers of the industry news source MD+DI (Medical Device and Diagnostic Industry).

Established more than four decades ago, MD+DI provides two opportunities annually for a business to be named “Company of the Year”: through selection by its editorial team and through a poll of MD+DI readers.
 
The editorial team recently spotlighted Hologic as its top pick for 2021, then followed up with an announcement that Hologic also won the readers’ poll for the second straight year.
 

“Hologic continues to gain momentum across the entire spectrum of our business, and we are poised to make an even bigger difference in the days ahead – for women and all those who depend on them,” said Hologic Chairman, President, and CEO Steve MacMillan. “We appreciate the editors and readers of MD+DI for validating the talent and dedication of Hologic’s purpose-driven staff.”

MD+DI said its readers praised Hologic’s exceptional contributions to women’s health, including the unprecedented Hologic Global Women’s Health Index. “Their mission to impact women’s health is unsurpassed by any other company,” one voter wrote. Another reader described Hologic as “a driver in early detection and treatment options for women all over the world.”
 
For its own award, the MD+DI editorial team highlighted Hologic’s increasing diversification as a strength that allows the company to play two leading roles globally: helping societies manage COVID-19 with trusted testing for the SARS-CoV-2 virus while helping reinvigorate routine screenings that enable early detection and treatment of breast and cervical cancers, sexually transmitted infections, uterine fibroids, and other conditions.

All three Hologic divisions have recently broadened their product portfolios with acquisitions, a key factor in the MD+DI editorial team’s evaluation process.

  • Hologic’s Breast and Skeletal Health Solutions Division has further widened its continuum of care by purchasing Somatex Medical Technologies, which develops minimally invasive devices for tumor diagnostics, biopsy procedures, and other therapies.
  • The GYN Surgical Solutions Division has extended its leadership in treating uterine fibroids with the acquisition of Acessa and entered the high-potential market of vessel sealing technologies with the purchase of Bolder Surgical.
  • The Diagnostic Solutions Division has enlarged its footprint by buying Biotheranostics, which makes two molecular tests for breast and metastatic cancers; acquiring Diagenode, which specializes in epigenetics and develops dozens of molecular tests for bacterial, viral, and parasitic infections; and acquiring Mobidiag, which focuses on diagnostic systems for smaller labs, tests for acute-care settings, and devices that provide “real-time” rapid testing.

 

Read the original article here.